Atreca Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BCEL Over the counter 8731 https://www.atreca.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atreca Inc

Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome - Dec 26th, 2023 1:30 pm
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives - Nov 14th, 2023 9:30 pm
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross - Sep 21st, 2023 12:00 pm
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% - Aug 14th, 2023 2:51 pm
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring - Aug 10th, 2023 8:05 pm
3 Penny Stocks to Catapult You Into the Millionaires’ Club - Jul 13th, 2023 5:03 pm
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate - Jun 28th, 2023 12:57 pm
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting - Jun 5th, 2023 12:00 pm
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments - May 10th, 2023 8:05 pm
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting - Apr 26th, 2023 8:05 pm